News
Warfarin dose capping avoided supratherapeutic INRs in hospitalized elderly
March 30, 2018
SAN DIEGO – Limiting the initial dose of warfarin to 2.5 mg or less for hospitalized patients aged 85 years and older led to significant reductions in supratherapeutic INRs.
Article
Many VTE patients live in fear of the next event
March 29, 2018
An estimated 41% of patients who experience a VTE fear another clot often or almost all the time.
Video
VIDEO: Andexanet alfa effectively reverses factor Xa anticoagulant
March 21, 2018
ORLANDO – Now that reversal is possible prescriptions for the already-popular direct Factor Xa inhibitor, anticoagulants should spike higher.
News
Beware of polypharmacy in patients taking warfarin
March 20, 2018
SAN DIEGO – The incidence of polypharmacy among patients on warfarin therapy appears to peak at age 75.
News
Ticagrelor noninferior to clopidogrel in terms of major bleeds in STEMI
March 11, 2018
New STEMI data answer some but not all questions.
Article
A simplified risk prediction model for patients presenting with acute pulmonary embolism
February 21, 2018
Is there a simplified risk prediction model to identify those with low risk pulmonary embolism (PE) who can be treated as outpatients?
Article
Anticoagulation use in new-onset secondary atrial fibrillation
February 16, 2018
Is anticoagulant use in patients with new-onset atrial fibrillation secondary to acute coronary syndrome, acute pulmonary disease, or sepsis associated with a reduction in ischemic stroke or an increase in bleeding risk?
Article
Rivaroxaban versus warfarin in mild acute ischemic stroke secondary to atrial fibrillation
February 12, 2018
Clinical question: Is rivaroxaban as effective and safe as warfarin immediately following minor acute ischemic stroke from atrial fibrillation?
News
Controversy surrounds calf vein thrombosis treatment
January 30, 2018
CHICAGO – Anticoagulation, filter, or surveillance? Large retrospective study provides answers.
News
Triple therapy in question
January 16, 2018
Clinical question: In patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention (PCI), is dabigatran plus a P2Y12 inhibitor safer than, and as efficacious as, triple therapy with warfarin?